Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 9/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | IDH2 | P48735 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25179790 | 0.86 | CTSC (0.73) | CTSC | |
| SCHEMBL4140858 | 0.85 | CTSC (0.67) | CTSCSYKIDH2 | |
| SCHEMBL658303 | 0.85 | CTSC (0.57) | CTSCAPPSYKTP53POLB | |
| SCHEMBL4131488 | 0.84 | KDM4E (0.59) | CTSCSYKMAPTIDH2LMNA | |
| SCHEMBL4175837 | 0.81 | SYK (0.51) | SYKMAPTLMNAEGFR | |
| SCHEMBL9945496 | 0.80 | EGFR (0.61) | SYKPOLBEGFR | |
| SCHEMBL655633 | 0.80 | SYK (0.72) | SYKEGFRABCG2 | |
| SCHEMBL6210167 | 0.79 | IGF1R (0.52) | APPEGFR | |
| SCHEMBL1774193 | 0.78 | IGF1R (0.68) | SYKEGFR | |
| SCHEMBL787987 | 0.77 | EGFR (0.62) | CTSCIDH2LMNAAREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | KIF5B, KIF5C, KIF2C | CTSC 2513/4885APP 2929/4885SYK 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.